StockData
Molecular Partners AG logo

Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30
$3.01−0.08 (-2.59%)

Close on Nov 12, 2026Market cap $121.53MP/E –Yield –

Earnings

Molecular Partners's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
Issued
Mar 13, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Molecular Partners's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Mar 13, 2026before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Molecular Partners's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total operating expensesFY202645 – 55–NewMar 13, 2026

Guidance history

Every forecast Molecular Partners put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 13, 2026total operating expensesFY202645 – 55New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Molecular Partners filed with the SEC as exhibits to Form 8-K or 6-K

  1. Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy
    6-K
  2. Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
    6-K
  3. Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
    6-K
  4. Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
    6-K
  5. Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
    6-K
  6. Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
    6-K
  7. Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
    6-K
  8. Condensed consolidated interim financial statements (unaudited)
    6-K
  9. Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
    6-K
  10. Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
    6-K
  11. Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
    6-K
  12. Molecular Partners Reports Highlights and Financial Results for Full Year 2025
    6-K
  13. 6-K exhibit EX-99.1
    6-K
  14. Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
    6-K
  15. Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
    6-K

See a number that looks wrong?